Ropivacaine
| Evidence Level: L3 | Predicted Indications: 4 |
Table of Contents
Ropivacaine: From Local Anaesthesia to Migraine Disorder
One-Sentence Summary
Ropivacaine is a long-acting amide local anaesthetic, marketed in India as an injectable for regional anaesthesia and nerve blocks. The TxGNN model predicts it may be useful for migraine disorder, with 2 clinical trials and 3 publications currently supporting this direction. This evidence is small and mostly observational.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence records compiled for this report (a local anaesthetic used for regional anaesthesia and nerve blocks) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 0.9965 |
| Evidence Level | L3 |
| India Market Status | Listed in a compiled Indian medicine price dataset (19 of 19) – CDSCO approval status is not included in this data |
| Number of Listed Products | 19 (valid: 19) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, ropivacaine is a long-acting amide local anaesthetic that blocks voltage-gated sodium channels. It is already used to numb nerves for pain control.
In migraine, ropivacaine is used in regional nerve blocks (sphenopalatine ganglion, stellate ganglion, trigeminal and occipital branches) and in trigger point injections. Blocking pain signals and parasympathetic outflow through the trigeminovascular system may reduce peripheral and central sensitisation. The effect is local and procedural, not systemic.
The very high TxGNN score fits this sodium channel and pain pathway link. However, the clinical support is modest and varied, so the score should be treated as a hypothesis, not proof.
Other predicted indications were weaker. Migraine with brainstem aura likely scores high (0.9955) because the TxGNN model (deep learning) may reflect similarities it learned between related diseases, not biological evidence, and nerve blocks are not known to act on its mechanism. Nephrogenic syndrome of inappropriate antidiuresis (0.9941) and dysthymic disorder (0.9915) have no plausible mechanistic link and no clinical evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03666663 | Phase 4 | Completed | 10 | Randomised, double-blind, placebo-controlled trial of sphenopalatine ganglion block with nasal anaesthetics for migraine prevention. Very small, so it cannot support efficacy conclusions, and the use of ropivacaine as the study drug is not confirmed. |
| NCT00680823 | NA | Completed | 150 | Paraspinal intramuscular ropivacaine injection for headache in a paediatric emergency department. Evidence for migraine is indirect because the condition studied is headache. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17244105 | 2007 | Cohort | Pain Med | Ropivacaine trigger point inactivation evaluated for preventing severe migraine over 12 weeks |
| 35331152 | 2022 | Cohort (observational) | BMC Anesthesiol | Ultrasound-guided stellate ganglion block assessed for relieving migraine pain and improving quality of life |
| 24284858 | 2013 | Case series | Pain Physician | A revised transnasal topical sphenopalatine ganglion block for headache and facial pain |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 154070 | Naropin 0.2% Injection (AstraZeneca) | Vial of 30 ml injection | Not stated in licence records |
| 191096 | Ropizuva 2mg Injection (Abbott) | Ampoule of 1 ml injection | Not stated in licence records |
| 192133 | Ropizuva 7.5mg Injection (Abbott) | Ampoule of 1 ml injection | Not stated in licence records |
| 184883 | Ropin 0.2% Injection (Neon Laboratories) | Vial of 20 ml injection | Not stated in licence records |
| 192840 | Rocaine 5mg Injection (Gland Pharma) | Vial of 10 ml injection | Not stated in licence records |
All 19 registrations are single-ingredient injectables and all are currently valid.
Safety Considerations
- Disease-level cautions (from the knowledge graph, not label text): Contraindication links were found for chronic obstructive pulmonary disease, respiratory failure, asthma, kidney disease, liver disease, biliary tract disease, cardiovascular and heart disease, cor pulmonale, myasthenia gravis and other neuromuscular junction disease, butyrylcholinesterase deficiency, inflammatory bowel disease, intestinal obstruction, paralytic ileus, benign prostatic hyperplasia, urethral stricture, intracranial hypertension, and substance abuse or dependence. These come from a knowledge graph and should be checked against the official package insert.
- Drug Interactions: 64 interactions are recorded. Examples at moderate level include obeticholic acid, liposomal morphine, deferasirox and fostamatinib. Many others are minor (for example cimetidine, clarithromycin, miconazole, clotrimazole, caffeine, cobicistat, ticagrelor, aprepitant) or of unknown severity (for example epinephrine, atropine, heparin, omeprazole, simvastatin).
- Systemic exposure: Ropivacaine carries cardiac and central nervous system toxicity risks if systemic exposure occurs, so any new use needs careful dosing and monitoring.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanism is plausible and a few small studies point to a possible role in migraine, but the evidence is limited to a very small trial, an indirect headache trial and observational reports. It is not enough to justify moving forward as a repurposing candidate. At this stage it is best treated as a research question.
To proceed, the following is needed:
- Adequately powered randomised controlled trials of ropivacaine nerve blocks or trigger point injections in migraine, with confirmed comparators
- Package insert warnings and contraindications from the India regulator, and approved indication text for the existing licences
- Mechanism of action data
- Assessment of route and procedural compatibility, since the proposed use is a local injection procedure and not a systemic therapy
- A safety plan covering local anaesthetic systemic toxicity and the disease-level cautions above
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.